pre-miRNA Information | |
---|---|
pre-miRNA | mmu-mir-122 |
Genomic Coordinates | chr18: 65248861 - 65248926 |
Synonyms | Mirn122a, mmu-mir-122, Mir122a |
Description | Mus musculus miR-122 stem-loop |
Comment | The mature sequence shown here represents the most commonly cloned form from large-scale cloning studies . |
RNA Secondary Structure | ![]() |
Mature miRNA Information | |
---|---|
Mature miRNA | mmu-miR-122-5p |
Sequence | 6| UGGAGUGUGACAAUGGUGUUUG |27 |
Evidence | Experimental |
Experiments | Cloned |
Putative Targets |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | Igf2 | ||||||||||||||||||||
Synonyms | AL033362, Igf-2, Igf-II, M6pr, Mpr, Peg2 | ||||||||||||||||||||
Description | insulin-like growth factor 2 | ||||||||||||||||||||
Transcript | NM_001122736 | ||||||||||||||||||||
Other Transcripts | NM_001122737 , NM_010514 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on Igf2 | |||||||||||||||||||||
3'UTR of Igf2 (miRNA target sites are highlighted) |
>Igf2|NM_001122736|3'UTR 1 ATCAAATTATGTGGTAATTCTGCAATGTAGTACCATCAATCTGTGACCTCCTCTTGAGCAGGGACAGTTCCATCACGTCC 81 CACACTAAGATCTCTCTGCTCCACTCCCTCCCCAGGTTTCTCCTTACCCACCCCCATGCCCCGCCTCCCCACATCAGGCT 161 GTTCCCCTTGCCCCACACCATCGGGCAAGGGGATCTCAGCAGTTCTAAAAAACCAAATTTGATTGGCTCTAAACAACCCA 241 ATTGACACCCCCCAAATTATATATTCACATTAAAAAAAACTTTAAAAACTACAGTCCCTTTAAAAACAAATTGGCTTTTA 321 AGAAATTCCATAACTGATAATCTAAAAATTAAATAACTAAAGAAATTAATTGGCTAAAAACATACTAAAAATTAATTGGC 401 TTAAAAACAATTGGCAAAATCAAATAATTCGGCGCCCCCCCCCCTTCATCTTCTTTCCATTTGGATCTTTAGTCAAATTG 481 GCTAAGACTTGGATCCCAGAACCCAAGAAGAAAGGAAGGGGACCCAAAATTTTGCAGGTGGCATGTCATTGCTTCAGTGC 561 CCTCTCCTTATCCCAAGCACCTTTAGTGTAAAGCTGGCTGAGAACAACAATAGCCGCCCAAACTCTTTCTTCACTGGTCA 641 TTCCATCACAAATGTCCCCCATGTCACCAAGGGGGCTGGGTGAAAGAACCCAAGGAGAAGAACAGAACATGAAAACTGGA 721 AATAGAACTTAATTGGCACAAGCCCCCAGTCCCAAAATCTCACTTTTCCCTACCTACCCTAAAAAGCACATGATTATACT 801 CACACCCACAGGCATTAACACACACATACACATAACACATATGCACACACACACACACACACACACACACACACACACAG 881 AGGTATGCACACCCACATAATTGGATGAAAACATTGAAATGGCTGAACAACTTCGATTTGAACCACATTCCCCAAAACAA 961 GGCCCATCCCAAATTTCCTGAGCAGTTTGCATGGTTTGAGCTCTCCTCCCAATCCATCTAGTTTCTGCTGCTGCTTATTG 1041 GCTCTATGTGTGACCAGGCTGCTAGTTCTGTCTTTCTCAGTGAGGGAGGTGTTCTAGCAAGGCTCAATTCCATCTAAGCA 1121 CCTGTCCACATGGTGAGCCCGGTGCTCCCCAACCACCCCCGCCATGAGGACCAATGACTAGCCAGTGTAGAATAAGTTTG 1201 GCCAGATAAGGAGATGGCACTGCCAAGTGATACATGCTGCCCAAGTAACCTGACCCCTAGTTGTGCTCCTGGGAGGAAAG 1281 ATCTGGGGGACAACCCCTACCCTGAGCACACCTATGGGCCATCTTTGTCAGTCTCCTGGGGAGCCCCCGCTTTTTAGGGG 1361 CTCCCCAGGAGACTCACACTGATGTGGGGAGTGTGGGAAGTCTGGCGGTTGGAGGGGTGGGTGGGGGGCAGTGGGGGCTG 1441 GGTGGGGGGAGCTATGGGTAGGAAGTGGTCCCAGAGAGGTTTTAGGTGGAAGAATCAGGAGGAGTCACAGGTCAACTTGC 1521 AGAATTACTGAAGAATTAGGACCCCAAATTTTATGCCAATTGATCTATTCCCCTCTTTTTATTTCTGGGGCCGGTTTTTT 1601 CCTTTTTTTTTTAATCCCTCCTTAGCTTTTTATGCGCTCATAATCAATTGTACCCATTCCCTACATAACGGGAGCAGTGA 1681 TCAGGTAATGAATGCATCGAGCCATCAACACCAGCTAGAGCCATCAACACCGGCTACCACAATGTCCTGCTCTCCACAAC 1761 CTTGATTTTTTTTTTTATCTCTCTCTATCGCTTGGCCTGAGTTGGGAGTGGAGTCTCTGTGGGGTGCTGGCCACGCACCC 1841 ACAGAGAAATAAAAGGAATTGAGAAGGTCGCTACCTGGCCTGACTTCTGGGGACAGTGGCTGGTCCCCAGAAGTTCTGAG 1921 GAGTGGAGGGGGCGTGGGGCAGTGTCCCCTCAGGTGTTAGGAAGGTGCTCGGAGGCCACAAAAGATGGGGCTCCCAGCTG 2001 GCCACTGCCAGTTGGGGGGGAAGGGGATAGAGATGTGAGAGTAGACAGGTTACATCAGGCGGGAGCAAGTGGCTGCCTTC 2081 TGAGCATTTGGGGGAGAACCTCTCCCGTCCCTCAGTGTCATCTTGCCCACTCCTCAGCACCCCACCTTGCCCCCAGGAGG 2161 TCTGGAGCTCTACAGACCTCCTGGGGGCAAGGTGGGGTGAGGCCCGGAGTTGGGGAAGCTAGGAGGCTTAAAGCCTACAG 2241 AGCCAGGAGAACTGTATACACGGGGTCATCTGGGCCCTGGGGCCTGAGGGTCTGGCGAGCCGTAGCAGCCACTCCACGGT 2321 GCCTAGGACTGCGGCGGGGAACAGGGCGGCTGGAGGTTTACCTCACCCCCACTTCTGCTTCCAGTGCAGTCCCCCTGCCC 2401 AACAGTCCAACTAGCAATCTAGAGGCCTGAGGCTTCTGGGCCCAGGTGACAGGACTGGCACCACCCTGGGGGCGGTGTGT 2481 GTCAGCCAAGCATGGCACAGAGGGTCCCTCAGCAAGTGCCTAAAGAATGGGCCATTTGGAACATTGGACAGAAACTCAAA 2561 GAGTAAATTGTTATAATTGGAGACTATGAATTGGCCTGGTATCCAAAACATCTCGAGGCACCCTAAATTACCTGCCCATT 2641 TGGCTGGACACCCACCCAGTGTTAATATGCCTCGTGGGATGGGTGCTTTCAGGGGCATTTGCTGACCACCCTCTGTGTCC 2721 CCACATTTGCAGTTCTCCCCATCATAGGTCACCTTGATGCAGGCACCTCCCTGGCCTCCTATGCCTAGTGTGGCCCTCCA 2801 TCTTGTCTCTTCCCTACTGTCTTCAGTGGGATCCCCTCTTGGGTCCCTCCCTTTGTCATCATGTGAAGACTTCCCACGCG 2881 TCGAACGCCATATGTCACCTGTGCCACTGTCCATGTCATCCAGCAGTGGCCCCAGGTGTTTGCCTCAACTCAGTCCCTCT 2961 AACATGCATTTTCTGGCAAAATCCAAAGCTTGGGTTTTGTTTTTAACCTGTTAACGCTCGCAAACCTAATAAAGCATTTA 3041 AAATACTA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
Experimental Support 1 for Non-Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | xx |
Validation Method |
|
Conditions | KO-miR-122 mice |
Location of target site | 3'UTR |
Tools used in this research | miRanda , PITA , RNAhybrid , TargetScanS |
Original Description (Extracted from the article) |
...
Please refer to Supplemental Table 7 and Figure 7(A).
... - Tsai WC; Hsu SD; Hsu CS; Lai TC; Chen SJ; et al., 2012, The Journal of clinical investigation. |
Article |
- Tsai WC; Hsu SD; Hsu CS; Lai TC; Chen SJ; et al. - The Journal of clinical investigation, 2012
MicroRNA-122 (miR-122), which accounts for 70% of the liver's total miRNAs, plays a pivotal role in the liver. However, its intrinsic physiological roles remain largely undetermined. We demonstrated that mice lacking the gene encoding miR-122a (Mir122a) are viable but develop temporally controlled steatohepatitis, fibrosis, and hepatocellular carcinoma (HCC). These mice exhibited a striking disparity in HCC incidence based on sex, with a male-to-female ratio of 3.9:1, which recapitulates the disease incidence in humans. Impaired expression of microsomal triglyceride transfer protein (MTTP) contributed to steatosis, which was reversed by in vivo restoration of Mttp expression. We found that hepatic fibrosis onset can be partially attributed to the action of a miR-122a target, the Klf6 transcript. In addition, Mir122a(-/-) livers exhibited disruptions in a range of pathways, many of which closely resemble the disruptions found in human HCC. Importantly, the reexpression of miR-122a reduced disease manifestation and tumor incidence in Mir122a(-/-) mice. This study demonstrates that mice with a targeted deletion of the Mir122a gene possess several key phenotypes of human liver diseases, which provides a rationale for the development of a unique therapy for the treatment of chronic liver disease and HCC.
LinkOut: [PMID: 22820290]
|
86 mmu-miR-122-5p Target Genes:
Functional analysis:
ID![]() |
Target | Description | Validation methods |
![]() |
![]() |
|||||||
Strong evidence | Less strong evidence | |||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|||||
MIRT003075 | Tmem50b | transmembrane protein 50B | ![]() |
1 | 1 | |||||||
MIRT003076 | Lass6 | ceramide synthase 6 | ![]() |
1 | 1 | |||||||
MIRT003077 | Gpx7 | glutathione peroxidase 7 | ![]() |
1 | 1 | |||||||
MIRT003113 | Tgfbr1 | transforming growth factor, beta receptor I | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003114 | Sbk1 | SH3-binding kinase 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003117 | Hist1h1c | histone cluster 1, H1c | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003118 | Ddc | dopa decarboxylase | ![]() |
![]() |
2 | 1 | ||||||
MIRT003120 | Rell1 | RELT-like 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003121 | Bach1 | BTB and CNC homology 1, basic leucine zipper transcription factor 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003122 | Apob | apolipoprotein B | ![]() |
![]() |
2 | 1 | ||||||
MIRT003123 | P4ha1 | procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide | ![]() |
![]() |
2 | 1 | ||||||
MIRT003124 | Ccng1 | cyclin G1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003125 | Slc7a1 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 | ![]() |
![]() |
![]() |
3 | 3 | |||||
MIRT003126 | Gys1 | glycogen synthase 1, muscle | ![]() |
![]() |
2 | 2 | ||||||
MIRT003127 | Slc35a4 | solute carrier family 35, member A4 | ![]() |
![]() |
2 | 2 | ||||||
MIRT003128 | Hfe2 | hemochromatosis type 2 (juvenile) | ![]() |
![]() |
![]() |
3 | 3 | |||||
MIRT003129 | Tmed3 | transmembrane p24 trafficking protein 3 | ![]() |
![]() |
2 | 2 | ||||||
MIRT003132 | Bckdk | branched chain ketoacid dehydrogenase kinase | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT003133 | Aldoa | aldolase A, fructose-bisphosphate | ![]() |
![]() |
![]() |
![]() |
4 | 7 | ||||
MIRT003134 | Ndrg3 | N-myc downstream regulated gene 3 | ![]() |
![]() |
![]() |
![]() |
4 | 2 | ||||
MIRT003135 | Cd320 | CD320 antigen | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT003724 | Smarcd1 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT003725 | Rcan1 | regulator of calcineurin 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT003726 | Gde1 | glycerophosphodiester phosphodiesterase 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT004536 | Ccrn4l | nocturnin | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT005975 | Klf6 | Kruppel-like factor 6 | ![]() |
![]() |
![]() |
![]() |
4 | 1 | ||||
MIRT005976 | B2m | beta-2 microglobulin | ![]() |
1 | 1 | |||||||
MIRT005977 | Afp | alpha fetoprotein | ![]() |
1 | 1 | |||||||
MIRT005978 | Ccl2 | chemokine (C-C motif) ligand 2 | ![]() |
1 | 1 | |||||||
MIRT005979 | Csf3r | colony stimulating factor 3 receptor (granulocyte) | ![]() |
1 | 1 | |||||||
MIRT005980 | Ctgf | connective tissue growth factor | ![]() |
1 | 1 | |||||||
MIRT005981 | Cxcl13 | chemokine (C-X-C motif) ligand 13 | ![]() |
1 | 1 | |||||||
MIRT005982 | Cyp2b13 | cytochrome P450, family 2, subfamily b, polypeptide 13 | ![]() |
1 | 1 | |||||||
MIRT005983 | Dbp | D site albumin promoter binding protein | ![]() |
1 | 1 | |||||||
MIRT005984 | Igf2 | insulin-like growth factor 2 | ![]() |
1 | 1 | |||||||
MIRT005985 | Il1b | interleukin 1 beta | ![]() |
1 | 1 | |||||||
MIRT005986 | Jun | jun proto-oncogene | ![]() |
1 | 1 | |||||||
MIRT005987 | Per1 | period circadian clock 1 | ![]() |
1 | 1 | |||||||
MIRT005988 | Alpl | alkaline phosphatase, liver/bone/kidney | ![]() |
![]() |
2 | 1 | ||||||
MIRT005989 | Cs | citrate synthase | ![]() |
![]() |
2 | 1 | ||||||
MIRT005990 | Prom1 | prominin 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT005991 | Sox4 | SRY (sex determining region Y)-box 4 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT013527 | Uros | uroporphyrinogen III synthase | ![]() |
1 | 1 | |||||||
MIRT013528 | Ppox | protoporphyrinogen oxidase | ![]() |
1 | 1 | |||||||
MIRT013529 | Urod | uroporphyrinogen decarboxylase | ![]() |
1 | 1 | |||||||
MIRT013530 | Cpox | coproporphyrinogen oxidase | ![]() |
1 | 1 | |||||||
MIRT013531 | Fech | ferrochelatase | ![]() |
1 | 1 | |||||||
MIRT013532 | Hamp | hepcidin antimicrobial peptide | ![]() |
1 | 1 | |||||||
MIRT013533 | Tfr2 | transferrin receptor 2 | ![]() |
1 | 1 | |||||||
MIRT013534 | Smad4 | SMAD family member 4 | ![]() |
1 | 1 | |||||||
MIRT013535 | Smad7 | SMAD family member 7 | ![]() |
1 | 1 | |||||||
MIRT013536 | Bmpr1a | bone morphogenetic protein receptor, type 1A | ![]() |
1 | 1 | |||||||
MIRT013537 | Hba-a1 | hemoglobin alpha, adult chain 1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT013538 | Hmbs | hydroxymethylbilane synthase | ![]() |
![]() |
2 | 1 | ||||||
MIRT013539 | Mir17 | microRNA 17 | ![]() |
![]() |
2 | 1 | ||||||
MIRT013540 | Alas2 | aminolevulinic acid synthase 2, erythroid | ![]() |
![]() |
2 | 1 | ||||||
MIRT013541 | Mir451 | microRNA 451a | ![]() |
![]() |
2 | 1 | ||||||
MIRT013542 | Tfrc | transferrin receptor | ![]() |
![]() |
2 | 1 | ||||||
MIRT013543 | Socs2 | suppressor of cytokine signaling 2 | ![]() |
1 | 1 | |||||||
MIRT013544 | Slc35g1 | solute carrier family 35, member G1 | ![]() |
1 | 1 | |||||||
MIRT013545 | Camk2b | calcium/calmodulin-dependent protein kinase II, beta | ![]() |
1 | 1 | |||||||
MIRT013546 | Irf6 | interferon regulatory factor 6 | ![]() |
1 | 1 | |||||||
MIRT013547 | Rbl2 | RB transcriptional corepressor like 2 | ![]() |
1 | 1 | |||||||
MIRT013548 | Hfe | hemochromatosis | ![]() |
![]() |
2 | 1 | ||||||
MIRT013549 | Ccnd1 | cyclin D1 | ![]() |
![]() |
2 | 1 | ||||||
MIRT054338 | Pkm | pyruvate kinase, muscle | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054339 | Tfdp2 | transcription factor Dp 2 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT054340 | E2f1 | E2F transcription factor 1 | ![]() |
![]() |
![]() |
3 | 1 | |||||
MIRT579817 | Zfp113 | zinc finger protein 113 | ![]() |
1 | 1 | |||||||
MIRT580378 | Tmem206 | transmembrane protein 206 | ![]() |
1 | 2 | |||||||
MIRT581166 | Sec23ip | Sec23 interacting protein | ![]() |
1 | 1 | |||||||
MIRT582514 | March5 | membrane-associated ring finger (C3HC4) 5 | ![]() |
1 | 2 | |||||||
MIRT586941 | H2-T24 | histocompatibility 2, T region locus 24 | ![]() |
1 | 2 | |||||||
MIRT591859 | Iffo2 | intermediate filament family orphan 2 | ![]() |
1 | 1 | |||||||
MIRT592160 | Paxip1 | PAX interacting (with transcription-activation domain) protein 1 | ![]() |
1 | 1 | |||||||
MIRT592189 | Nanog | Nanog homeobox | ![]() |
1 | 2 | |||||||
MIRT592792 | Cdh12 | cadherin 12 | ![]() |
1 | 1 | |||||||
MIRT597026 | Thap1 | THAP domain containing, apoptosis associated protein 1 | ![]() |
1 | 1 | |||||||
MIRT597210 | Snhg11 | small nucleolar RNA host gene 11 | ![]() |
1 | 1 | |||||||
MIRT601300 | Zfp949 | zinc finger protein 949 | ![]() |
1 | 1 | |||||||
MIRT602608 | Chrna1 | cholinergic receptor, nicotinic, alpha polypeptide 1 (muscle) | ![]() |
1 | 1 | |||||||
MIRT602960 | Xpo7 | exportin 7 | ![]() |
1 | 1 | |||||||
MIRT603391 | Sgol2 | shugoshin 2A | ![]() |
1 | 1 | |||||||
MIRT604008 | Ggps1 | geranylgeranyl diphosphate synthase 1 | ![]() |
1 | 1 | |||||||
MIRT605553 | Ppp1r16b | protein phosphatase 1, regulatory (inhibitor) subunit 16B | ![]() |
1 | 1 | |||||||
MIRT606204 | Sfxn4 | sideroflexin 4 | ![]() |
1 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|